• Home
  • ShieldVax Set to Launch Vaccine Production in Ethiopia by 2026, Announces Health Minister

ShieldVax Set to Launch Vaccine Production in Ethiopia by 2026, Announces Health Minister


Addis Ababa – Ethiopia is set to bolster its vaccine production capabilities, as ShieldVax, an enterprise under the Public Enterprises Holding and Administration Agency, plans to deliver fill finish vaccine by 2026 and vaccine drug substance by the end of 2027. This announcement was made by Ethiopia’s Health Minister, Lia Tadesse.



According to Ethiopian News Agency, the foundation stone for ShieldVax Enterprise’s new project at the Kilinto Industrial Park was laid today, marking a significant step in Ethiopia’s efforts to establish a local vaccine manufacturing industry. The Minister highlighted that developing a strong ecosystem is essential for building the local manufacturing sector. “ShieldVax Enterprise is poised to play a crucial role in regional collaboration and solidarity, aligning with the Africa CDC’s priorities,” Lia stated, underscoring the project’s significance in achieving the ambitious goal of producing 60 percent of Africa’s vaccines by 2040.



The establishment of ShieldVax Enterprise is a testament to the Ethiopian government’s commitment to enhancing defenses against current and future health challenges. Lia emphasized that the enterprise symbolizes resilience, adaptability, and a collective resolve to secure a healthier future for upcoming generations.



Jean Kaseya, Director-General of the Africa Center for Disease Control and Prevention (Africa-CDC), represented at the event, commented on Ethiopia’s approach to vaccine and pharmaceutical manufacturing. “Ethiopia exemplifies both the challenges and the necessary solutions for Africa in this field,” he said, affirming the Africa CDC’s support for Ethiopia’s efforts in manufacturing medicines and vaccines.



Additionally, World Bank Country Director for Ethiopia, Ousmane Dione, highlighted Ethiopia’s national strategy to increase local pharmaceutical production from 20 to 60 percent and reduce reliance on imports. “The World Bank, along with the IFC, is planning an investor outreach to identify potential investments for the ShieldVax Enterprise at Kilinto Industrial Park,” Dione revealed, committing to continued technical assistance from the World Bank in support of the Ethiopian government’s endeavors.